Powering the Immune System to Transform Lives
Our Pipeline
A Deep, Broad Pipeline to Address Unmet Patient Need
Our deep and broad pipeline contains multiple clinical-stage and preclinical candidates for diseases with significant unmet patient need. We are moving with urgency to develop transformative medicines that have the potential to help improve the lives of millions of people around the world.
Hepatitis Delta
tobevibart ± elebsiran
- Collaborator:
- Alnylam
- Treatment Type:
- Treatment
- Phase:
- Phase 2,100%
Learn more about our therapeutic focus on Hepatitis Delta
Hepatitis B
elebsiran + PEG-IFN-α
- Collaborator:
- Alnylam
- Treatment Type:
- Treatment
- Phase:
- Phase 2,100%
tobevibart ± elebsiran ± PEG-IFN-α1
- Collaborator:
- Alnylam
- Treatment Type:
- Treatment
- Phase:
- Phase 2,100%
elebsiran + TLR82 + PD-13
- Collaborator:
- Alnylam / Gilead
- Treatment Type:
- Treatment
- Phase:
- Phase 2,100%
Learn more about our therapeutic focus on Hepatitis B
HIV
VIR-1388
- Collaborator:
- BMGF, NIAID and HVTN**
- Treatment Type:
- Prevention
- Phase:
- Phase 1,100%
Cure: mAb combination
- Collaborator:
- BMGF
- Treatment Type:
- Treatment
- Phase:
- Pre-clinical,100%
Learn more about our therapeutic focus on HIV
RSV & MPV
VIR-8190*
Preclinical antibody candidates
- Treatment Type:
- Prevention
- Phase:
- Pre-clinical,100%
Learn more about our therapeutic focus on RSV & MPV
Influenza
VIR-2981 (Influenza A+B)
ADCs
- Treatment Type:
- Prevention
- Phase:
- Pre-clinical,100%
Learn more about our therapeutic focus on Influenza A & B
Pre-Cancerous HPV Lesions
VIR-1949
- Treatment Type:
- Treatment
- Phase:
- Pre-clinical,100%
Learn more about our therapeutic focus on Pre-Cancerous HPV Lesions
COVID-19
VIR-7229
- Treatment Type:
- Prevention
- Phase:
- Pre-clinical,100%
Sotrovimab***
- Collaborator:
- GSK
- Treatment Type:
- Treatment (Early)
- Phase:
- Authorized,100%
Learn more about our therapeutic focus on COVID-19
1: MARCH trial (Part B), PREVAIL platform trial (THRIVE/STRIVE sub-protocols)
2: GS-9688
3: nivolumab
* Per the collaboration agreement announced in February 2021, Vir and GSK are continuing to advance new monoclonal antibody therapeutics for RSV.
** Bill and Melinda Gates Foundation, National Institute of Allergy and Infectious Diseases, and HIV Vaccine Trials Network.
*** Sotrovimab for early treatment by IV currently has marketing approval, temporary authorization or emergency use authorization in >30 countries. In April 2022, the FDA deauthorized sotrovimab‘s use in all US regions. Commercialized by GSK.
ADCs = Antibody-drug conjugates